PL3562821T3 - Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydaz - Google Patents
Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydazInfo
- Publication number
- PL3562821T3 PL3562821T3 PL17829043T PL17829043T PL3562821T3 PL 3562821 T3 PL3562821 T3 PL 3562821T3 PL 17829043 T PL17829043 T PL 17829043T PL 17829043 T PL17829043 T PL 17829043T PL 3562821 T3 PL3562821 T3 PL 3562821T3
- Authority
- PL
- Poland
- Prior art keywords
- alteration
- activity
- preparation
- methods
- conditions associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382660 | 2016-12-28 | ||
EP17829043.3A EP3562821B9 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
PCT/IB2017/058438 WO2018122746A1 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3562821T3 true PL3562821T3 (pl) | 2021-06-14 |
Family
ID=57777485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17829043T PL3562821T3 (pl) | 2016-12-28 | 2017-12-27 | Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydaz |
Country Status (13)
Country | Link |
---|---|
US (1) | US11440898B2 (pl) |
EP (1) | EP3562821B9 (pl) |
JP (1) | JP7144863B2 (pl) |
CN (1) | CN110494432B (pl) |
AU (1) | AU2017388300B2 (pl) |
BR (1) | BR112019013593A2 (pl) |
CA (1) | CA3047700A1 (pl) |
DK (1) | DK3562821T3 (pl) |
ES (1) | ES2862374T3 (pl) |
IL (1) | IL267553B (pl) |
PL (1) | PL3562821T3 (pl) |
PT (1) | PT3562821T (pl) |
WO (1) | WO2018122746A1 (pl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
CZ20013833A3 (cs) | 1999-04-28 | 2002-02-13 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
US6706731B2 (en) | 2000-02-09 | 2004-03-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase |
DE60239000D1 (de) | 2001-09-07 | 2011-03-03 | Seikagaku Kogyo Co Ltd | Carbazuckeraminderivate und mittel gegen störungenff enthalten |
WO2004078114A2 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
MXPA06008257A (es) | 2004-01-23 | 2006-08-31 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
EP1720855A4 (en) | 2004-03-02 | 2008-12-17 | Smithkline Beecham Corp | HEMMER OF ACT ACTIVITY |
WO2005086904A2 (en) | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
US7919487B2 (en) | 2004-11-10 | 2011-04-05 | Synta Pharmaceuticals Corporation | Heteroaryl compounds |
WO2006058201A2 (en) | 2004-11-23 | 2006-06-01 | Reddy Us Therapeutics, Inc. | Heterocyclic and bicyclic compounds, compositions and methods |
JP2008521862A (ja) | 2004-12-01 | 2008-06-26 | デブジェン エヌブイ | イオンチャンネル、特にkvファミリーのイオンチャンネルと相互作用する5−カルボキサミド置換チアゾール誘導体 |
US20060173019A1 (en) | 2005-01-14 | 2006-08-03 | Solomon Ungashe | Heteroaryl sulfonamides and CCR2 |
AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
CA2627830A1 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CN101360740A (zh) | 2005-11-16 | 2009-02-04 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶 |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
EP2064185B1 (en) | 2006-08-10 | 2011-06-08 | Ferrer Internacional, S.A. | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
EP1903034A1 (en) | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosugar glycoconjugates |
CA2696113A1 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
WO2009049421A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
EP2217572B1 (en) | 2007-11-16 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
ES2337435B8 (es) | 2008-10-22 | 2011-07-19 | Consejo Superior De Investigaciones Cientificas (Csic) (25%) | Compuestos potenciadores de la actividad de glicosidasas mutantes. |
EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
CA2778349C (en) | 2009-10-19 | 2018-12-04 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
BR112013023774B1 (pt) | 2011-03-18 | 2022-01-11 | Genzyme Corporation | Inibidores de glicosilceramida sintase |
IN2014MN00226A (pl) | 2011-07-05 | 2015-09-25 | Lupin Ltd | |
BR122019019582B1 (pt) | 2011-12-30 | 2021-07-13 | Hanmi Pharm. Co., Ltd. | Compostos derivados de tieno[3,2-d]pirimidina, composição farmacêutica contendo os ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase |
WO2014043296A1 (en) * | 2012-09-14 | 2014-03-20 | Eternity Bioscience Inc. | Aminoisoquinoline derivatives as protein kinase inhibitors |
EP3632426A1 (en) | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
US20160168132A1 (en) * | 2013-07-31 | 2016-06-16 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
WO2015069594A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Gsk-3 inhibitors |
US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
PE20170009A1 (es) | 2014-04-25 | 2017-03-17 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 |
WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
WO2016120808A1 (en) * | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
-
2017
- 2017-12-27 CA CA3047700A patent/CA3047700A1/en active Pending
- 2017-12-27 PT PT178290433T patent/PT3562821T/pt unknown
- 2017-12-27 CN CN201780086786.5A patent/CN110494432B/zh active Active
- 2017-12-27 US US16/473,966 patent/US11440898B2/en active Active
- 2017-12-27 DK DK17829043.3T patent/DK3562821T3/da active
- 2017-12-27 WO PCT/IB2017/058438 patent/WO2018122746A1/en unknown
- 2017-12-27 PL PL17829043T patent/PL3562821T3/pl unknown
- 2017-12-27 BR BR112019013593-6A patent/BR112019013593A2/pt active Search and Examination
- 2017-12-27 EP EP17829043.3A patent/EP3562821B9/en active Active
- 2017-12-27 ES ES17829043T patent/ES2862374T3/es active Active
- 2017-12-27 JP JP2019535381A patent/JP7144863B2/ja active Active
- 2017-12-27 AU AU2017388300A patent/AU2017388300B2/en active Active
-
2019
- 2019-06-20 IL IL267553A patent/IL267553B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3562821B9 (en) | 2021-05-26 |
JP7144863B2 (ja) | 2022-09-30 |
JP2020514284A (ja) | 2020-05-21 |
CN110494432B (zh) | 2022-08-12 |
BR112019013593A2 (pt) | 2020-01-07 |
IL267553A (en) | 2019-08-29 |
WO2018122746A1 (en) | 2018-07-05 |
ES2862374T3 (es) | 2021-10-07 |
AU2017388300A1 (en) | 2019-07-11 |
CA3047700A1 (en) | 2018-07-05 |
US20200071294A1 (en) | 2020-03-05 |
AU2017388300B2 (en) | 2022-03-31 |
US11440898B2 (en) | 2022-09-13 |
EP3562821B1 (en) | 2020-12-02 |
EP3562821A1 (en) | 2019-11-06 |
CN110494432A (zh) | 2019-11-22 |
DK3562821T3 (da) | 2021-02-15 |
PT3562821T (pt) | 2021-03-03 |
IL267553B (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269444B (en) | New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs | |
IL256687B (en) | Isolated tau-binding antibody and its use in treatment and diagnosis | |
HK1223628A1 (zh) | β- 新的 -酮- β-烷基膽烷酸衍生物在製備奧貝膽酸以及其在醫藥領域的用途 | |
EP3250589A4 (en) | Therapeutic and diagnostic agents | |
GB201519128D0 (en) | Solid forms and methods of preparing the same | |
GB201513098D0 (en) | Catalytically active protein aggregates and methods for producing the same | |
HK1257519A1 (zh) | 用於 galgt2 基因治療的方法和物質 | |
IL258023A (en) | Systems and methods for trigger-based modification of privacy settings associated with posts | |
EP3348643A4 (en) | MODIFIED INTERLEUKIN 12 AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS | |
GB201406172D0 (en) | Therapy and pharmaceutical composition | |
EP3294763C0 (en) | PRODUCTION OF GLUCANASE AND METHODS OF USE THEREOF | |
IL267553B (en) | Iso-quinone compounds, methods for their preparation and their medical uses in conditions related to a change in the activity of beta-galactosidase | |
GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
EP3407890C0 (de) | Pharmazeutische zubereitung und deren verwendung in der behandlung von viraler laryngitis | |
ZA201607353B (en) | Bicyclic derivatives and pharmaceutical composition including the same | |
PT3177596T (pt) | Processo melhorado para a preparação de eslicarbazepina e acetato de eslicarbazepina | |
GB201519644D0 (en) | Therapy and pharmaceutical composition | |
ZA201505621B (en) | Carbodithioates with spermicidal activity and process for preparation thereof | |
PL3070078T3 (pl) | Niesymetryczne bisakrydyny o działaniu przeciwnowotworowym i ich zastosowania | |
HRP20182167T1 (hr) | Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba | |
GB201617761D0 (en) | Medicament and assay | |
GB201617726D0 (en) | Medicament and assay | |
EP3344661C0 (en) | IRON POLYSACCHARIDE COMPLEXES AND METHOD FOR THE PRODUCTION THEREOF | |
HUE056121T2 (hu) | Kompozíció UV-B terápia hatékonyságának növelésére, eljárás annak elõállítására, és alkalmazása | |
AU2015900260A0 (en) | Therapeutic and diagnostic agents |